new glp-1 receptor agonists Molecules and Emerging Indications for Medicines Color coding Comparing Ozempic, Wegovy and Other

Moreover, last year a separate study showed that 91% of obese individuals receiving a weekly dose of 15 mg Tirzepatidea recently developed GLP-1R/GIPR dual agonist, lost 5% of their body mass with 36% of participants on the same dosage losing at least 25% ( While these data are astoundingwith yearly progress in efficacy, we should consider that around 9% of patients receiving these game-changer treatments (Table 1)

[DOI] [PubMed] [Google Scholar] 10

Obesity is a significant risk factor to a number of diseases such as diabetes, heart disease, and cancer

Gastrointestinal side effects are the most frequently reported adverse reactions with GLP-1 receptor agonists, particularly during the initial weeks of treatment or following dose escalation